Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
NEW YORK - Zimmer Biomet Holdings Inc. (NYSE:ZBH), the medical device maker, reported first-quarter results that beat analyst expectations on Monday.
The company’s shares gained 1.46% in premarket trading following the release.
The Warsaw, Indiana-based company posted adjusted earnings of $1.81 per share for the quarter ended March 31, surpassing the consensus estimate of $1.77. Revenue rose 1.1% YoY to $1.91 billion, also topping analysts’ projections of $1.89 billion.
"We are proud of our team’s continued execution and performance to start the year, as we delivered solid first quarter results and advanced our bold innovation agenda," said Ivan Tornos, Zimmer Biomet’s President and Chief Executive Officer.
The company reported 3.7% YoY growth in U.S. hip sales, driven by its revamped portfolio including the Z1 Triple-Taper Femoral Hip System. However, knee sales growth was more muted at 0.6% YoY.
For the full year 2025, Zimmer Biomet lowered its adjusted earnings guidance to $7.90-$8.10 per share, below the consensus of $8.21, to account for its recent acquisition of Paragon 28 and currency impacts.
The company also updated its 2025 revenue growth forecast to 5.7-8.2%, up from its previous outlook of 1.0-3.5%, reflecting the Paragon 28 deal.
Zimmer Biomet’s shares have risen about 1.5% year-to-date, underperforming the S&P 500’s 7% gain over the same period.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.